RxDoctor Payments Data

Erin Scott, NP

Adult Health · Beaufort, SCNPI 1144599929

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 44 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$348
  • Lilly USA, LLC$265
  • Atricure, Inc.$95
  • Novo Nordisk$87
  • AstraZeneca$64
  • Boston Scientific$60
  • plus $204 from 7 others

What the payments were for

  • Food & beverage$1,122100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,122 in reported general payments places this provider in the 55th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$80,516
Medicare patients
264
Services billed
1,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$59,038
JanuviaSitagliptin Phosphate29$34,083
JardianceEmpagliflozin17$25,123
EliquisApixaban17$24,539
FarxigaDapagliflozin Propanediol16$21,977
LinzessLinaclotide17$12,738
JanumetSitagliptin Phos/Metformin Hcl12$6,647
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$5,444
Atorvastatin Calcium357$3,454
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$2,605
Omeprazole133$2,365
Levothyroxine Sodium256$2,232
Rosuvastatin Calcium209$1,933
Duloxetine Hcl47$1,818
Valsartan47$1,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$87$59,03836 claims
AstraZenecaFarxiga$64$21,97716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 292 adult health providers in South Carolina.

Other adult health in Beaufort

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →